Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data

Andreas D. Meid, Anna Medem, Dirk Heider, Jürgen-Bernhard Adler, Christian Günster, Hanna M. Seidling, Renate Quinzler, Hans-Helmut König and Walter E. Haefeli ()
Additional contact information
Andreas D. Meid: University of Heidelberg
Anna Medem: University of Heidelberg
Dirk Heider: University Medical Center Hamburg-Eppendorf
Jürgen-Bernhard Adler: Wissenschaftliches Institut der AOK (WIdO)
Christian Günster: Wissenschaftliches Institut der AOK (WIdO)
Hanna M. Seidling: University of Heidelberg
Renate Quinzler: University of Heidelberg
Hans-Helmut König: University Medical Center Hamburg-Eppendorf
Walter E. Haefeli: University of Heidelberg

Drug Safety, 2017, vol. 40, issue 2, No 6, 133-144

Abstract: Abstract Introduction Drugs that potentially prolong the QT interval carry the risk of life-threatening Torsades de pointes (TdP) ventricular arrhythmia. Objective The objective of this study was to investigate the potential additive risk for ventricular arrhythmia with concomitant prescriptions of QT-prolonging drugs. Methods Claims data for persons aged ≥65 years between 2010 and 2012 in Germany were analyzed and all cases hospitalized for ventricular arrhythmia were selected. In a case-crossover analysis, exposure with QT-prolonging drugs according to the Arizona Center for Education and Research on Therapeutics (AZCERT) classification of ‘known,’ ‘conditional,’ and ‘possible’ TdP risk was determined in respective event and control windows preceding hospitalization. Conditional logistic regression was applied to derive odds ratios (ORs). Results Among 6,849,622 health-insured persons, we identified 2572 patients newly hospitalized for ventricular arrhythmia. Drugs with ‘known’ risk were more frequently prescribed in the event window than in the control window (309 vs. 239; P

Keywords: Ventricular Arrhythmia; Claim Data; Terfenadine; Event Window; Cardiac Repolarization (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-016-0477-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:40:y:2017:i:2:d:10.1007_s40264-016-0477-y

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-016-0477-y

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().